Touch Bionics, the Livingston-based maker of artificial upper limb components, increased turnover by 23.6% to £18.3m in 2025, up from £14.8m the previous year.
Profit for the year rose 26.1% to £5.8m, from £4.6m, and gross profit increased to £11.2m from £9.2m. Profit before tax was £7.4m, compared with £6.0m in 2024.
In their strategic report, the directors said the increases in turnover and profit were “primarily driven by higher sales volumes during the year”.
Europe accounted for the largest share of sales, at £11.4m, up from just under £7m in 2024. Sales in North America fell to £6.9m from £7.8m.
The company spent almost £3m on research and development during the year, up from about £2m in 2024. The accounts say that spending related mostly to developing new functions for its i-Limb and i-Digits products.
Net assets fell to £8.4m from £16.6m. No dividend was paid during 2025, but the accounts record that a dividend of £14m was recommended during the year and paid on 5 January 2026.
The company employed an average of 49 people during the year, compared with 50 in 2024.
The directors said the business would remain profitable for the foreseeable future and that strategies were in place to increase sales growth.
In Case You Missed It:
ECI Partners lifts the lid on what CEOs often get wrong about private equity
Livingston-based Randex eyes £10M growth with Sales Geek Scotland deal
Nike upsizing deal cements Livingston Designer Outlet’s retail leadership
Commsworld targets next turnover double as Edinburgh network provider hires first Chief Revenue Officer
Touch Bionics is part of the Embla Medical group. Its immediate parent is Össur UK Holding Limited, and its ultimate parent is William Demant Invest A/S of Denmark.
